{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:26:22Z","timestamp":1790735182564,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.pnpbp.2022.110553","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T11:55:22Z","timestamp":1648209322000},"page":"110553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia"],"prefix":"10.1016","volume":"117","author":[{"given":"Isadora Lopes","family":"Cortez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naielly S.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Francisco C.","family":"Pedrazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Del Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mechoulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe V.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco S.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pnpbp.2022.110553_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/YPG.0000000000000047","article-title":"Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population","volume":"24","author":"Bae","year":"2014","journal-title":"Psychiatr. Genet."},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110553_bb0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1176\/ajp.156.4.596","article-title":"Symptom correlates of prepulse inhibition deficits in male schizophrenic patients","volume":"156","author":"Braff","year":"1999","journal-title":"Am. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.pnpbp.2022.110553_bb0020","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","article-title":"Models of schizophrenia in humans and animals based on inhibition of NMDA receptors","volume":"32","author":"Buben\u00edkov\u00e1-Vale\u0161ov\u00e1","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"November 2018","key":"10.1016\/j.pnpbp.2022.110553_bb0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2018.11.043","article-title":"Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons","volume":"360","author":"Canseco-Alba","year":"2019","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110553_bb0035","first-page":"269","article-title":"Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and cb1 receptor antagonism in rats","volume":"20","author":"Delis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2022.110553_bib341","article-title":"Dopamine in schizophrenia: A review and reconceptualization","author":"Devis","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0040","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","article-title":"Cognitive impairment in schizophrenia is the core of the disorder","author":"Elvevag","year":"2000","journal-title":"Crit. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110553_bb0045","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12035-016-9697-5","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia","volume":"54","author":"Fakhoury","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0050","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-006-0658-y","article-title":"The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice","author":"Fejgin","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-006-0658-y","article-title":"The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice","author":"Fejgin","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0060","series-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","article-title":"Endocannabinoid system in psychotic and mood disorders, a review of human studies","volume":"vol. 106","author":"Garani","year":"2021"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pnpbp.2022.110553_bb0070","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2022.110553_bib346","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.23872","article-title":"Sex, hormones, and genotype interact to influence psychiatric disease, treatment, and behavioral research","author":"Gobinath","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0075","doi-asserted-by":"crossref","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"SUPPL.2","key":"10.1016\/j.pnpbp.2022.110553_bb0080","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pnpbp.2013.06.005","article-title":"Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice","volume":"46","author":"Gomes","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"Issue 2","key":"10.1016\/j.pnpbp.2022.110553_bb0090","article-title":"Cannabis use and the risk of developing a psychotic disorder","volume":"7","author":"Hall","year":"2008","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110553_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2007.05.005","article-title":"The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia","volume":"18","author":"Hamdani","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2022.110553_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11920-010-0148-0","article-title":"Assessment of pharmacotherapy for negative symptoms of schizophrenia","volume":"12","author":"Hanson","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2022.110553_bb0115","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1111\/j.1476-5381.2011.01381.x","article-title":"A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia\/reperfusion injury","volume":"165","author":"Horv\u00e1th","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2016.07.014","article-title":"The role of genes, stress, and dopamine in the development of schizophrenia","author":"Howes","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2022.110553_bb0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain cannabinoid CB2 receptor in schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"16","key":"10.1016\/j.pnpbp.2022.110553_bb0130","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s00213-014-3481-x","article-title":"CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice","volume":"231","author":"Khella","year":"2014","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2022.110553_bb0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neuropharm.2010.09.004","article-title":"The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects","volume":"60","author":"Kinsey","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0140","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","author":"Koethe","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0145","article-title":"The neurobiology of drug addiction","author":"Koob","year":"1997","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110553_bb0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12640-017-9702-4","article-title":"The impact of CB2 receptor ligands on the MK-801-induced hyperactivity in mice","volume":"31","author":"Kruk-Slomka","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2019.2508","article-title":"Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits","author":"Legge","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"April","key":"10.1016\/j.pnpbp.2022.110553_bb0160","article-title":"CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP\/PS1 mice","volume":"707","author":"Li","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.pnpbp.2022.110553_bb0165","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2019.03.040","article-title":"Mechanisms of cannabinoid CB 2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area","volume":"42","author":"Ma","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/S0304-3959(01)00321-9","article-title":"CB2 cannabinoid receptor-mediated peripheral antinociception","author":"Malan","year":"2001","journal-title":"Pain."},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110553_bb0190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00212846","article-title":"Dopaminergic stimulation disrupts sensorimotor gating in the rat","volume":"94","author":"Mansbach","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0195","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bcp.2018.09.013","article-title":"Role of the endocannabinoid system in drug addiction","volume":"157","author":"Manzanares","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110553_bb0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.pnpbp.2022.110553_bib343","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","author":"Moreira","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110553_bb0205","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110553_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.neures.2009.07.009","article-title":"Prepulse inhibition of the startle response with chronic schizophrenia: a replication study","volume":"65","author":"Moriwaki","year":"2009","journal-title":"Neurosci. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2022.110553_bb0215","first-page":"2","article-title":"Schizophrenia: From developmental deviance to dopamine dysregulation","volume":"18","author":"Murray","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110553_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2022.110553_bb0225","article-title":"The DBA\/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?","volume":"156","author":"Olivier","year":"2001","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110553_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001640","article-title":"Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects","volume":"3","author":"Onaivi","year":"2008","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pnpbp.2022.110553_bb0235","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/npp.2011.34","article-title":"Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice","volume":"36","author":"Ortega-Alvaro","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.pnpbp.2022.110553_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-3223(99)00148-1","article-title":"Impaired prepulse inhibition of acoustic startle in schizophrenia","volume":"47","author":"Parwani","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bib344","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110352","article-title":"Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum","author":"Pedrazzi","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/S0304-3940(97)13346-8","article-title":"The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of prepulse inhibition","author":"Rasmussen","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104749","article-title":"Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors","volume":"156","author":"Rodrigues da Silva","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pnpbp.2017.07.012","article-title":"Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative","volume":"79","author":"Silva","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bib342","author":"Soethoudt","year":"2017","journal-title":"Nat. Commun"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00613","article-title":"Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia","author":"Sonnenschein","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00613","article-title":"Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia","volume":"11","author":"Sonnenschein","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2004.11.031","article-title":"Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia","author":"Stefani","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2004.11.031","article-title":"Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia","author":"Stefani","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2022.110553_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2007.02.031","article-title":"Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A\/2C receptors","volume":"564","author":"Su","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2007.02.031","article-title":"Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A\/2C receptors","volume":"564","author":"Su","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.pnpbp.2022.110553_bb0305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00008877-200006000-00002","article-title":"Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon","volume":"11","author":"Swerdlow","year":"2000","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110553_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/sj.mp.4001029","article-title":"CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia","author":"Ujike","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110553_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.pnpbp.2022.110553_bb0325","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB2 receptors modulate cocaine\u2019s actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-8993(97)00568-4","article-title":"Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats","author":"Yan","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2022.110553_bb0335","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.111.631044","article-title":"Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage\/microglial activation concomitant to neuroprotection","author":"Zarruk","year":"2012","journal-title":"Stroke."},{"issue":"46","key":"10.1016\/j.pnpbp.2022.110553_bb0340","doi-asserted-by":"crossref","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","article-title":"Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2022.110553_bib345","doi-asserted-by":"crossref","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","author":"Gobira","year":"2013","journal-title":"Revista Brasileira de Psiquiatria"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584622000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584622000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:59:02Z","timestamp":1759521542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584622000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":68,"alternative-id":["S0278584622000458"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2022.110553","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2022.110553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110553"}}